comparemela.com

Latest Breaking News On - Bymichael monostra - Page 1 : comparemela.com

New vitamin D consensus guideline, debates highlight ENDO annual meeting

Endocrinology providers and researchers will gather in Boston beginning Saturday as the Endocrine Society holds its 2024 annual meeting. ENDO 2024 will take place from Saturday through Tuesday at the Boston Convention & Exhibition Center. This year’s meeting program includes three plenary sessions, two sessions on new Endocrine Society consensus guidelines, three debates, 36 oral

Diabetes does not raise risk for subsequent hip fracture after incident fracture

Older adults with type 1 or type 2 diabetes who sustain an incident hip fracture have a similar likelihood for a subsequent hip fracture as those without diabetes, according to study data published in Bone. “Among incident hip fracture patients, we found no strong overall association of type 2 diabetes or type 1 diabetes with increased risk of subsequent hip fractures, but diabetes patients

Tirzepatide lowers body weight, improves glycemic control for adults with type 1 diabetes

Tirzepatide lowers body weight, improves glycemic control for adults with type 1 diabetes
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

GLP-1s not tied to higher risk for surgical complications for adults with diabetes

Adults with diabetes who used a GLP-1 receptor agonist and underwent surgery requiring general anesthesia had similar odds for postsurgical complications as those receiving other oral diabetes medications, according to study data. The findings were published in Diabetes, Obesity and Metabolism.

Adults with obesity, preexisting CVD maintain weight loss with semaglutide at 4 years

Adults with obesity lost 10.2% of their body weight at 4 years with the GLP-1 receptor agonist semaglutide, according to an analysis of data from the SELECT trial. As Healio previously reported, the SELECT trial randomly assigned 17,604 adults with obesity and established cardiovascular disease to once-weekly semaglutide 2.4 mg (Wegovy, Novo Nordisk) or placebo. In the trial’s primary

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.